Medicare AdvantagePrior AuthLow impact
Kygevvi® (doxecitine and doxribtimine) oral powder packet (New)
Humana·Genetics, Pediatrics, Neurology +1 more·Medicare Advantage
Effective date
Apr 22, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now covers Kygevvi® (doxecitine and doxribtimine) oral powder for treating thymidine kinase 2 deficiency, but requires prior authorization. Providers must attest to genetically confirmed TK2D diagnosis for approval.
Action Required
By April 22, 2026: Billing team must update prior authorization procedures for Kygevvi® prescriptions. Ensure providers document genetically confirmed thymidine kinase 2 deficiency (TK2D) diagnosis attestation before submitting claims. Claims without prior authorization will be denied.